BRIEF-Prokidney Reports Statistically And Clinically Significant Topline Results For The Phase 2 REGEN-007 Trial

Reuters

08 Jul

BRIEF-Prokidney Reports Statistically And Clinically Significant Topline Results For The Phase 2 REGEN-007 Trial

July 8 (Reuters) - ProKidney Corp PROK.O:

PROKIDNEY REPORTS STATISTICALLY AND CLINICALLY SIGNIFICANT TOPLINE RESULTS FOR THE PHASE 2 REGEN-007 TRIAL EVALUATING RILPARENCEL IN PATIENTS WITH CHRONIC KIDNEY DISEASE AND DIABETES
PROKIDNEY CORP - NO SERIOUS ADVERSE EVENTS OBSERVED WITH RILPARENCEL TREATMENT
PROKIDNEY CORP - GROUP 1 SHOWED 78% IMPROVEMENT IN EGFR SLOPE AFTER RILPARENCEL
PROKIDNEY CORP - GROUP 2 SHOWED 50% IMPROVEMENT IN EGFR SLOPE AFTER RILPARENCEL

Source text: ID:nGNX68jypy

Further company coverage: PROK.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2549541856"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2549541856\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2549541856?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-08 19:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2549541856","market":"fut","top_or_hot":-1,"title":"BRIEF-Prokidney Reports Statistically And Clinically Significant Topline Results For The Phase 2 REGEN-007 Trial","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Prokidney Reports Statistically And Clinically Significant Topline Results For The Phase 2 REGEN-007 Trial </title></head><body><p><span>July 8 (Reuters)</span><span> - </span>ProKidney Corp <span>PROK.O</span>:</p><ul><li><p>PROKIDNEY REPORTS STATISTICALLY AND CLINICALLY SIGNIFICANT TOPLINE RESULTS FOR THE PHASE 2 REGEN-007 TRIAL EVALUATING RILPARENCEL IN PATIENTS WITH CHRONIC KIDNEY DISEASE AND DIABETES</p></li><li><p>PROKIDNEY CORP - NO SERIOUS ADVERSE EVENTS OBSERVED WITH RILPARENCEL TREATMENT</p></li><li><p>PROKIDNEY CORP - GROUP 1 SHOWED 78% IMPROVEMENT IN EGFR SLOPE AFTER RILPARENCEL</p></li><li><p>PROKIDNEY CORP - GROUP 2 SHOWED 50% IMPROVEMENT IN EGFR SLOPE AFTER RILPARENCEL</p></li></ul><p>Source text: <span>ID:nGNX68jypy</span></p><p>Further company coverage: <span>PROK.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Prokidney Reports Statistically And Clinically Significant Topline Results For The Phase 2 REGEN-007 Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Prokidney Reports Statistically And Clinically Significant Topline Results For The Phase 2 REGEN-007 Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-07-08 19:26</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Prokidney Reports Statistically And Clinically Significant Topline Results For The Phase 2 REGEN-007 Trial </title></head><body><p><span>July 8 (Reuters)</span><span> - </span>ProKidney Corp <span>PROK.O</span>:</p><ul><li><p>PROKIDNEY REPORTS STATISTICALLY AND CLINICALLY SIGNIFICANT TOPLINE RESULTS FOR THE PHASE 2 REGEN-007 TRIAL EVALUATING RILPARENCEL IN PATIENTS WITH CHRONIC KIDNEY DISEASE AND DIABETES</p></li><li><p>PROKIDNEY CORP - NO SERIOUS ADVERSE EVENTS OBSERVED WITH RILPARENCEL TREATMENT</p></li><li><p>PROKIDNEY CORP - GROUP 1 SHOWED 78% IMPROVEMENT IN EGFR SLOPE AFTER RILPARENCEL</p></li><li><p>PROKIDNEY CORP - GROUP 2 SHOWED 50% IMPROVEMENT IN EGFR SLOPE AFTER RILPARENCEL</p></li></ul><p>Source text: <span>ID:nGNX68jypy</span></p><p>Further company coverage: <span>PROK.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PROK","symbol_name":"ProKidney Corp.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250708:nTUA6JWM8W:1","article_id":"2549541856","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2549541856","pubTimestamp":1751973978,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Prokidney Reports Statistically And Clinically Significant Topline Results For The Phase 2 REGEN-007 Trial July 8 (Reuters) - ProKidney Corp PROK.O:PROKIDNEY REPORTS STATISTICALLY AND CLINICALLY","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PROK":"ProKidney Corp.","BK4139":"生物科技"},"translate_title":"BRIEF-Prokidney报告了2期REGEN-007试验具有统计学和临床意义的顶线结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PROK":0.9},"content_text":"BRIEF-Prokidney Reports Statistically And Clinically Significant Topline Results For The Phase 2 REGEN-007 Trial July 8 (Reuters) - ProKidney Corp PROK.O:PROKIDNEY REPORTS STATISTICALLY AND CLINICALLY SIGNIFICANT TOPLINE RESULTS FOR THE PHASE 2 REGEN-007 TRIAL EVALUATING RILPARENCEL IN PATIENTS WITH CHRONIC KIDNEY DISEASE AND DIABETESPROKIDNEY CORP - NO SERIOUS ADVERSE EVENTS OBSERVED WITH RILPARENCEL TREATMENTPROKIDNEY CORP - GROUP 1 SHOWED 78% IMPROVEMENT IN EGFR SLOPE AFTER RILPARENCELPROKIDNEY CORP - GROUP 2 SHOWED 50% IMPROVEMENT IN EGFR SLOPE AFTER RILPARENCELSource text: ID:nGNX68jypyFurther company coverage: PROK.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}